Onkologie. 2024:18(4):259-261 | DOI: 10.36290/xon.2024.053

Trifluridine/tipiracil in the 4th line treatment of metastatic distal esophageal and cardia cancer

Marián Liberko1, 2, Renata Soumarová1, 2
1 Onkologická klinika, 3. LF UK a FNKV, Praha
2 3. lékařská fakulta Univerzity Karlovy, Praha

This case report describes a patient with metastatic distal esophageal and cardia cancer who was treated with several lines of systemic therapy with repeated response and disease control. In the fourth-line, trifluridine/tipiracil treatment, a treatment response significantly superior to that observed in the TAGS registration study was observed. At the same time, effective trifluridine/tipiracil treatment did not lead to deterioration in the patient's general condition and had minimal impact on quality of life.

Keywords: trifluridin, tipiracil, systemic therapy, metastatic gastric cancer.

Accepted: October 1, 2024; Published: October 7, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Trifluridine/tipiracil in the 4th line treatment of metastatic distal esophageal and cardia cancer. Onkologie. 2024;18(4):259-261. doi: 10.36290/xon.2024.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018;19(12):e668. doi: 10.1016/S1470-2045 (18)30843-X. PMID: 30355453. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.